Global Oral Polio Vaccines (OPV) Market Size By Type (Trivalent OPV, Bivalent OPV), By Application (Public, Private), By Region, And Segment Forecasts, 2023 to 2032

The Global Oral Polio Vaccines (OPV) Market was valued at USD 1.4 billion in 2023 and is projected to reach USD 2.1 billion by 2031, expanding at a CAGR of 5.2% during the forecast period from 2023 to 2031. The market growth is driven by intensified global immunization programs, the continued threat of poliovirus in endemic regions, and strong support from international health organizations. As the world aims to achieve total eradication of polio, OPV remains a cornerstone of mass vaccination efforts due to its ease of administration and ability to induce community immunity.

Drivers

1. Global Eradication Initiatives:

Ongoing global efforts, led by organizations such as WHO, UNICEF, and GAVI, continue to promote mass immunization drives using OPV. These programs significantly boost demand, particularly in low-income countries.

2. Cost-Effectiveness and Ease of Administration:

OPV is preferred over inactivated polio vaccine (IPV) in large-scale immunization campaigns because it is less expensive and does not require trained healthcare professionals for administration.

3. Strong Public-Private Partnerships:

Collaborative funding and distribution models from global stakeholders are strengthening vaccine accessibility and facilitating rapid response in outbreak zones.

Restraints

1. Vaccine-Derived Poliovirus (VDPV) Risks:

Although rare, mutations of OPV can lead to circulating vaccine-derived polioviruses (cVDPV), prompting concerns about long-term reliance on OPV, especially in regions with low immunization coverage.

2. Regulatory and Transition Challenges:

The planned global transition from OPV to IPV, particularly in countries approaching polio-free status, introduces complexity in procurement strategies and hinders consistent market growth.

Opportunity

1. Expanded Surveillance and Emergency Stockpiling:

Growing emphasis on surveillance and the establishment of global vaccine stockpiles present significant opportunities for manufacturers to scale up OPV production and distribution.

2. Innovation in OPV Formulations:

The development of novel oral polio vaccines (nOPV2), designed to reduce the risk of VDPV, offers growth potential in both endemic and non-endemic regions seeking safe and effective immunization tools.

Market by System Type Insights

The market is segmented into Trivalent OPV (tOPV) and Bivalent OPV (bOPV). As of 2023, bOPV held the largest market share, driven by its efficacy against the two most persistent poliovirus serotypes (types 1 and 3). However, nOPV2 is emerging rapidly, backed by emergency use listings and favorable clinical trial results.

Market by End-Use Insights

Public Health Initiatives, particularly those led by governmental and international bodies, accounted for the highest share of the OPV market in 2023. These include national immunization days, mass campaigns, and outbreak response programs. The private sector, including travel clinics and private pediatric care providers, represents a smaller yet steadily growing segment.

Market by Regional Insights

Asia-Pacific led the global OPV market in 2023, primarily due to high birth rates and focused eradication campaigns in countries like Pakistan and Afghanistan. Africa follows closely, benefiting from GAVI-supported programs. Meanwhile, North America and Europe have transitioned largely to IPV, but remain active in funding and global distribution of OPV in at-risk regions.

Competitive Scenario

Leading players in the Global Oral Polio Vaccines Market include GlaxoSmithKline plc, Sanofi S.A., Serum Institute of India Pvt. Ltd., Bio Farma, and Bharat Biotech International Limited. These companies are engaged in bulk supply agreements with UNICEF and PAHO, expansion of cold chain capabilities, and development of safer vaccine strains like nOPV2.

Scope of Work – Global Oral Polio Vaccines (OPV) Market

Key Market Developments

2023: WHO granted Emergency Use Listing for nOPV2, accelerating its adoption in outbreak-prone regions.

2022: Serum Institute of India signed a long-term supply agreement with UNICEF to deliver over 200 million OPV doses annually.

2021: Bio Farma initiated collaboration with the Indonesian government to enhance domestic OPV production capacity and reduce dependency on imports.

FAQs

1) What is the current market size of the Global Oral Polio Vaccines (OPV) Market?

The market was valued at USD 1.4 billion in 2023.

2) What is the major growth driver of the Global Oral Polio Vaccines (OPV) Market?

The primary growth driver is the global push for polio eradication and mass immunization campaigns.

3) Which is the largest region during the forecast period in the Global Oral Polio Vaccines (OPV) Market?

Asia-Pacific is the largest region, owing to high demand in polio-endemic countries.

4) Which segment accounted for the largest market share in the Global Oral Polio Vaccines (OPV) Market?

The bivalent OPV (bOPV) segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Oral Polio Vaccines (OPV) Market?

Key players include GlaxoSmithKline plc, Sanofi S.A., Serum Institute of India, Bio Farma, and Bharat Biotech.